Adequacy of dialysis and differences in hematocrit among dialysis facilities

American Journal of Kidney Diseases

Volumn 36, Issue 6, 2000, Pages 1166-1174

  Ifudu, Onyekachi ^a,b,c   Uribarri, Jaime ^a,b,c   Rajwani, Imran ^a,b,c   Vlacich, Vera ^a,b,c   Reydel, Kathy ^a,b,c   Delosreyes, Georgina ^a,b,c   Friedman, Eli A ^a,b,c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Nephrology Foundation of Brooklyn   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Adequacy of dialysis; Anemia; Dialysis facility; End stage renal disease (ESRD); End Stage Renal Disease (ESRD) Network; Erythropoietin (EPO); Hemodialysis (HD); Intravenous iron; Underdialysis; Urea reduction ratio (URR)

Indexed keywords

ERYTHROPOIETIN; IRON BINDING PROTEIN; UREA;

ADULT; AGED; ANEMIA; ARTICLE; DIALYSIS; DOSE CALCULATION; DRUG RESPONSE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL DEPARTMENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UREA BLOOD LEVEL;

EID: 0033647433     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.19830     Document Type: Article

References (48)

1. Hematocrit levels and hospitalization risks in hemodialysis patients
2. Hematocrit level and associated mortality in hemodialysis patients
3. Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996
4. Anemia in hemodialysis patients: Variables affecting this outcome predictor
5. Severity of acquired immunodeficiency syndrome and the response to erythropoietin in uremia
6. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
7. Effect of increased hemodialysis dose on endogenous erythropoietin production in endstage renal disease
8. DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
9. Erythropoietin requirements remain high in erythropoietin resistant patients after iron repletion
10. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
11. Relationship between anaemia and adequacy of continuous ambulatory peritoneal dialysis
12. When do plasma levels of azotemic indices indicate inadequacy of peritoneal dialysis ?
13. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure
14. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure
15. Effect of erythropoietin in normal men and in patients with renal insufficiency
16. Separation of an inhibitor of erythropoiesis in 'middle molecules' from hemodialysate from patients with chronic renal failure
17. Exceptionally high serum erythropoietin activity in an anephric patient with severe anemia
18. Polyamines in the anemia of end-stage renal disease
19. Hematopoietic inhibitors in chronic renal failure: Lack of in vitro specificity
20. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure
21. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis
22. Response of uremic bone marrow cells to erythropoietin in vitro
23. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction
24. Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study
25. Factors influencing anemia in dialysis patients. A special survey by the EDTA-ERA Registry
26. Intravenous iron supplementation for the treatment of the anaemia of moderate to severe chronic renal failure patients not receiving dialysis
27. The measurement of reticuloendothelial iron release using iron-dextran
28. Diagnosis of iron deficiency anaemia in renal failure patients during the post-erythropoietin era
29. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis
30. Iron deficiency
31. Pharmacokinetics of iron(III)-hydroxidesucrose complex after a single intravenous dose in healthy volunteers
32. Erythrocyte changes, serum iron concentration and performance following iron injection in neonatal beef calves
33. Characteristics of iron dextran utilization in man
34. 59Fe-dextran complex in human subjects
35. Transferrin, iron, and serum lipids enhance or inhibit Mycobacterium avium replication in human macrophages
36. Increased incidence of gramnegative neonatal sepsis with intramuscular iron administration
37. Impaired bacteriological responses in babies after maternal iron dextran infusion
38. Parenteral iron causes increased lipid peroxidation in hemodialysis patients
39. Frequent intravenous iron dosing is associated with higher infectious deaths
40. Iron overload in hemodialysis patients increases the risk of bacteraemia: A prospective study
41. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
42. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey
43. Intravenous iron closing patterns and mortality
44. Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review
45. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers
46. The effect of injected iron on the absorption of iron in iron deficiency